Tyrosine Kinase-Inhibitors effective in epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCL)

被引：0
|
作者：
Pommer, Peter
机构：
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2016年 / 141卷 / 18期
关键词：
D O I：
10.1055/s-0042-110629
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1284 / 1284
页数：1
相关论文
共 50 条
  • [21] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Sequist, Lecia V.
    ONCOLOGIST, 2007, 12 (03): : 325 - 330
  • [22] Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
    Gao, Yuan
    Song, PingPing
    Li, Hui
    Guo, HongBo
    Jia, Hui
    Zhang, BaiJiang
    ONCOTARGETS AND THERAPY, 2016, 9 : 13 - 20
  • [23] Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Engelman, Jeffrey A.
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2008, 14 (10) : 2895 - 2899
  • [24] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S146 - S149
  • [25] De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Fujita, Yoshihiko
    Arao, Tokuzo
    Ito, Hiroyuki
    Fukuoka, Masahiro
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 399 - 400
  • [26] Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng
    Cho, Byoung-Chul
    Soo, Ross A.
    LUNG CANCER, 2016, 93 : 59 - 68
  • [27] Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
    Takeyasu, Y.
    Goto, Y.
    Morita, R.
    Sato, J.
    Murakami, S.
    Horinouchi, H.
    Fujiwara, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4416S - 4420S
  • [29] Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
    Chen, Kaiyan
    Yu, Xiaoqing
    Wang, Haiyang
    Huang, Zhiyu
    Xu, Yanjun
    Gong, Lei
    Fan, Yun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1179 - 1187
  • [30] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)
    Sun, Xin
    Xu, Shan
    Yang, Zunhua
    Zheng, Pengwu
    Zhu, Wufu
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2021, 31 (03) : 223 - 238
12345